Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

Immune checkpoints, such as programmed death-ligand 1 (PD-L1), limit T-cell function and tumor cells use this ligand to escape the anti-tumor immune response. Treatments with monoclonal antibodies blocking these checkpoints have shown long-lasting responses, but only in a subset of patients. This st...

Full description

Bibliographic Details
Main Authors: Jessica Bridoux, Katrijn Broos, Quentin Lecocq, Pieterjan Debie, Charlotte Martin, Steven Ballet, Geert Raes, Sara Neyt, Christian Vanhove, Karine Breckpot, Nick Devoogdt, Vicky Caveliers, Marleen Keyaerts, Catarina Xavier
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Biomolecules
Subjects:
Nanobody
PD-L1
site-specific
PET
gallium-68
Sortase A
Online Access:https://www.mdpi.com/2218-273X/10/10/1388

Internet

https://www.mdpi.com/2218-273X/10/10/1388

Similar Items